Dose study of AV-380 for cancer-related weight loss
Part of Cancer clinical trials.
This Phase 1 trial tests a new drug (AV-380) in people with solid tumor cancer who are losing weight and muscle because of cancer. It mainly helps researchers find a safe dose and see how the body responds, and it may offer a new option for cancer-related cachexia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older when you sign consent
- Have confirmed solid tumor cancer and be on standard treatment (SoC)
- Meet study criteria for cancer-related cachexia (not just eating less)
- Expect to live at least 3 months
- Have no known severe allergy to monoclonal antibody medicines
- Brain metastases/brain covering disease must be treated and stable for at least 2 weeks, if you have them
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called DS010 to see if it can help people with cancer-related weight loss and muscle loss (cachexia). The goal is to improve appetite and strength, which may help you feel better during cancer treatment.
This study tests a special form of megestrol acetate (a medicine that can help with appetite and weight gain) in people with advanced digestive system cancers who are about to start or are already taking a type of targeted therapy called a TKI. The goal is to see if it helps with cancer-related weight loss and wasting (cachexia).
This Phase 1 study tests how safe INCA33890 is in adults with advanced or metastatic solid cancers. Because it’s an early safety study, the main goal is to see how the body handles the drug and whether it causes side effects.
This study tests a new intravenous drug called ABBV-400 in people with certain advanced solid tumors that have not responded to other treatments. The goal is to see if it can slow or stop tumor growth and to check for side effects.
This study tests a new medicine (QLS2319) to see if it’s safe and can help people with cancer-related weight loss and muscle loss (cachexia). It’s for people whose daily activities aren’t severely limited by their cancer.
This trial tests an investigational injection called INB301 to see if it can help reduce weight loss and improve appetite in people with cancer-related wasting (cachexia). It is a phase 1/2 study, so it is one of the first times the drug is given to people, and safety is a key goal.
Hear when a new Cachexia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.